236 related articles for article (PubMed ID: 28819279)
41. MPN blast phase: clinical challenge and assessing response.
Mesa RA; Tibes R
Leuk Res; 2012 Dec; 36(12):1496-7. PubMed ID: 22999527
[No Abstract] [Full Text] [Related]
42. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
Gill H; Leung AY; Chan CC; Lau JS; Chan C; Yip SF; Liu H; Kho B; Mak V; Lee HK; Lin SY; Lau CK; Kwong YL
Hematology; 2016 Jan; 21(1):10-8. PubMed ID: 26292161
[TBL] [Abstract][Full Text] [Related]
43. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Barbui T; Thiele J; Vannucchi AM; Tefferi A
Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
[TBL] [Abstract][Full Text] [Related]
44. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
Tefferi A
Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
[TBL] [Abstract][Full Text] [Related]
45. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
46. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
[TBL] [Abstract][Full Text] [Related]
47. The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis?
Hasselbalch HC
Leuk Res; 2014 Oct; 38(10):1230-6. PubMed ID: 25149709
[TBL] [Abstract][Full Text] [Related]
48. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Mesa RA; Camoriano JK; Geyer SM; Wu W; Kaufmann SH; Rivera CE; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li CY; Tefferi A
Leukemia; 2007 Sep; 21(9):1964-70. PubMed ID: 17581608
[TBL] [Abstract][Full Text] [Related]
49. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Santos FP; Kantarjian HM; Jain N; Manshouri T; Thomas DA; Garcia-Manero G; Kennedy D; Estrov Z; Cortes J; Verstovsek S
Blood; 2010 Feb; 115(6):1131-6. PubMed ID: 20008298
[TBL] [Abstract][Full Text] [Related]
50. [Molecular pathophysiology and treatment overview of PV, ET and PMF].
Komatsu N
Rinsho Ketsueki; 2012 Oct; 53(10):1589-99. PubMed ID: 23037731
[No Abstract] [Full Text] [Related]
51. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
52. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.
Guy A; Bidet A; Ling C; Caumont C; Boureau L; Viallard JF; Parrens M
Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231
[TBL] [Abstract][Full Text] [Related]
53. A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
Verstovsek S; Savona MR; Mesa RA; Dong H; Maltzman JD; Sharma S; Silverman J; Oh ST; Gotlib J
Br J Haematol; 2017 Mar; 176(6):939-949. PubMed ID: 28220932
[TBL] [Abstract][Full Text] [Related]
54. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
55. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
56. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia.
Tefferi A; Lasho TL; Wolanskyj AP; Mesa RA
Blood; 2004 May; 103(9):3547-8. PubMed ID: 14701686
[TBL] [Abstract][Full Text] [Related]
57. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
58. What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?
Guglielmelli P; Rotunno G; Pacilli A; Vannucchi AM
Curr Hematol Malig Rep; 2015 Dec; 10(4):380-7. PubMed ID: 26431835
[TBL] [Abstract][Full Text] [Related]
59. The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters.
Catani L; Cavo M; Palandri F
Cells; 2021 Sep; 10(9):. PubMed ID: 34571965
[TBL] [Abstract][Full Text] [Related]
60. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.
Begna K; Abdelatif A; Schwager S; Hanson C; Pardanani A; Tefferi A
Blood Cancer J; 2016 May; 6(5):e427. PubMed ID: 27232929
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]